QIAstat-Dx mini gastrointestinal panel gets FDA clearance
Jan. 14, 2025—Qiagen announced FDA clearance of the first in a series of QIAstat-Dx gastrointestinal panel tests for clinical use.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
FDA clears Ventana DP 600 slide scanner
Jan. 13, 2025—Roche announced that its whole slide imaging system, Roche Digital Pathology Dx, has received an additional 510(k) clearance from the FDA. This clearance modifies the one the company received in June 2024 for Roche Digital Pathology Dx, which includes the Ventana DP 200 slide scanner, Roche’s digital pathology workflow software and a display, and now adds the Ventana DP 600 slide scanner. The Ventana DP 600 has 40 times the capacity of the DP 200 and uses the
Sysmex to distribute, service Sentinel SentiFIT in Canada
Jan. 7, 2025—Sysmex America has signed an agreement with Sentinel Diagnostics that grants Canadian rights to distribute and service Sentinel Diagnostics SentiFIT 270 and 800 analyzers as part of a new fecal immunochemical test.
ARUP launches assay for influenza A (H5) virus
Jan. 3, 2025—ARUP Laboratories has launched an assay for the detection and subtyping of influenza A (H5) virus.
Quest to provide clinical trial lab services for Mainz CRC test
Dec. 23, 2024—Mainz Biomed announced an agreement with Quest Diagnostics to support commercialization of the company’s next-generation screening test for colorectal cancer.
Roche gets CE mark for Cobas Mass Spec solution
Dec. 20, 2024—Roche announced it has received CE mark approval for its Cobas Mass Spec solution, including the Cobas i 601 analyzer and Ionify reagent pack of four assays for steroid hormones.
BD, Babson expand access to fingertip blood testing
Dec. 19, 2024—BD and Babson Diagnostics announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other large provider networks in settings like urgent cares, doctor’s offices, and other ambulatory care settings.
Deepull UllCore BSI test gets breakthrough device designation
Dec. 18, 2024—Deepull announced it has received breakthrough device designation from the FDA for its UllCore bloodstream infection test.
MeMed Severity test gets FDA breakthrough device designation
Dec. 10, 2024—MeMed announced that the FDA has granted breakthrough device designation to its MeMed Severity test.
BioFire tropical fever panel gets special 510(k) clearance
Dec. 9, 2024—BioMérieux announced that its BioFire FilmArray Tropical Fever panel has received FDA special 510(k) clearance.